NEW YORK – Nightingale Health said Tuesday that it is opening a US laboratory and has inked a deal to integrate its blood analysis and disease risk assessment technologies into Weill Cornell Medicine's clinical and research services.
Nightingale said it will disclose in the future the location of the laboratory and timing of its opening. However, the company said the laboratory will allow it to offer its proprietary blood analysis technology in the US and expand its partnerships within the medical research community.
Financial and other terms of the deal were not disclosed.
Nightingale's proprietary blood testing technology uses nuclear magnetic resonance to determine concentrations of readable molecules in a blood sample, and its software incorporates algorithm-based disease risk predictions, according to the company's website. The technology can provide comprehensive metabolic information including the identification of biomarkers such as amino acids, apolipoproteins, cholesterols, fatty acids, and triglycerides.
The deal with Cornell's Englander Institute for Precision Medicine will expand the availability of Nightingale's multi-disease risk prediction models and biomarker-based tests that can be used to replace clinical chemistry tests, among other technologies. The Englander Institute plans to use Nightingale's blood testing technology to implement comprehensive patient risk assessments that can be used to inform treatment, health checks, and screening programs for common chronic diseases.
"This initiative complements our global network of laboratories located in Finland, Singapore, the United Kingdom, and Japan and allows us to serve the most ambitious precision medicine and healthcare projects in the world," Teemu Suna, Nightingale founder and CEO, said in a statement.
Olivier Elemento, director of the Englander Institute, added that the institute has hopes to develop patient metabolic profiles that can be used to tailor treatments and advance precision medicine that can improve patient outcomes globally.